Virios Therapeutics, Inc. (VIRI) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET
CompanyParticipants
Greg Duncan – CEO
Ralph Grosswald – SVP, Operations
Angela Walsh – SVP, Finance & Treasurer
Conference Call Participants
David Bautz – Zacks Small Cap Research
Sean Lee – H.C. Wainwright & Co., LLC
Operator
Good morning, and welcome to the Virios Therapeutics, Inc. Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s call is being recorded at the company’s request.
At this time, I’d like to turn the call over to Angela Walsh, Senior Vice President of Finance and Treasurer for Virios Therapeutics. Please proceed, Angela.
Angela Walsh
Thank you. Good morning, everyone, and thank you for joining us on today’s conference call. We are pleased to be with you today to discuss Virios Therapeutics second quarter 2022 financial results, as well as to provide you with an update on the operational progress we have made during the past six months. Please note that our financial results press release is now available on our website. We’ll start today’s call with our CEO, Greg Duncan, providing you with a brief update on our corporate progress during the past quarter, and then I will return to review our second quarter financial results. In addition, Ralph Grosswald, our Senior Vice President of Operations, is with us for the question-and-answer portion of the call.
Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially from the information expressed or implied by these forward-looking statements. For more information regarding such risks and uncertainties, please see the risk factors outlined in the company’s filings